Genetic Study of Schizophrenia

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001486
First received: November 3, 1999
Last updated: August 16, 2014
Last verified: August 2014
  Purpose

This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.


Condition
Psychotic Disorder
Schizoaffective Disorder
Schizophrenia

Study Type: Observational
Official Title: A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 6150
Study Start Date: June 1995
Detailed Description:

Objective: Schizophrenia is a complex genetic disorder which likely involves many genes each producing a slight increase in risk. Finding weak-acting genes in complex genetic disorders has been challenging and will likely require a number of approaches and large clinical samples. Several strategies have emerged recently that appear to markedly improve the power of genetic studies for detecting such genes. These include using association (rather than linkage) and using intermediate phenotypes in addition to DMS-IV diagnosis.

Study Population: We propose to take advantage of these techniques by studying quantitative traits related to schizophrenia in patients, siblings, and controls.

Design: We will employ an association design, rather than linkage. Traits will include quantifiable neurobiological variables that have been implicated previously as possible phenotypes related to schizophrenia. These include tests of attention and cognition, and a variety of parameters using brain imaging and magnetoencephalography.

Outcome Measure: We will use several statistical methods to show that specific genetic polymorphisms affect these phenotypes, including case control and family based association studies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION/EXCLUSION CRITERIA:

Inclusion criteria for Siblings (probands and unaffected siblings):

  • Probands must have a DSM IV-R diagnosis of schizophrenia,schizoaffective disorder, psychosis N.O.S. or schizophreniform disorder.
  • Probands and Siblings must be between the ages of 18 and 55
  • Probands and Siblings must be free of major medical illnesses, but may have controlled hypertension, thyroid disease, or diabetes.
  • Probands and Siblings who do not have capacity to provide consent and are under guardianship can participate in the study if the guardian signs the informed consent and the research subject provides their written assent. A DPA is not utilized in this study.
  • Probands should be fluent in English language by age 5 due to specific requirements related to neurocognitive testing.

Exclusion Criteria for Siblings (probands and unaffected siblings):

  • Seizure disorder, mental retardation, organic brain damage or other neurological disease.
  • Previous history of illicit drug or alcohol abuse for five years or more.
  • Head trauma with loss of consciousness over 5 minutes from all but genetic sampling.
  • Documented metal in the body, e.g. from fixed dental bridges, orthodontia braces, IUDs containing metal or surgical screws.
  • Weight and height dimensions that result in size exceeding the capability of the MRI bore circumference is exclusionary.
  • Chemotherapy.

Siblings who do not qualify for the 2-day or 1-day study, may participate in the limited phenotyping arm in which only a psychiatric interview and a blood draw for genetic analysis (SCID-DNA) will be performed, case control analysis or be included as part of a trio (one parent, one sibling, one patient) to study genetic transmission from parents to offsprings.. All parents are eligible for the study.

Healthy Controls Inclusion Criteria:

To be eligible for this research study, healthy volunteers must be:

  • between the ages of 18 and 55
  • fluent in English language by age 5 due to specific requirements related to neurocognitive testing.

Healthy Controls Exclusion Criteria:

They will not be eligible if:

  • They have history of DSM IV-R psychiatric diagnosis or severe chronic medical illness at the time of the study.
  • If they have abused illicit drugs, prescription drugs or alcohol for over 5 years per DSM IV R criteria for substance abuse.
  • They may not be eligible for the 2-day or 1-day study if they have a first-degree relative with history of schizophrenia spectrum disorders. However, they may be included in the SCID_DNA or case control analyses..
  • Documented presence of metal such as orthodontia braces, surgical screws or IUD of metal composition.
  • Healthy volunteers must be free of learning disabilities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001486

Contacts
Contact: Karen Bartholomew, L.C.S.W. (301) 496-4304 bartholk@intra.nimh.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: Karen F Berman, M.D. National Institute of Mental Health (NIMH)
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00001486     History of Changes
Other Study ID Numbers: 950150, 95-M-0150
Study First Received: November 3, 1999
Last Updated: August 16, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Paranoia
Schizophrenic Research
Hallucinations
Delusions
Brain Scans
Negative Symptoms
Symptoms of Schizophrenia
Causes of Schizophrenia
Psychosis and Schizophrenia
Compensation
Schizophrenia
Schizoaffective Disorder
Psychosis
Manic-Depression

Additional relevant MeSH terms:
Schizophrenia
Disease
Psychotic Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Pathologic Processes

ClinicalTrials.gov processed this record on October 02, 2014